Home » Newsletters » BioWorld Science

BioWorld Science

April 23, 2010

View Archived Issues

Taisho identifies novel MCH1 receptor antagonists

Merck Serono claims novel PI3K inhibitors

Novel antibacterial agents identified by AstraZeneca

AstraZeneca discloses novel Janus kinase inhibitors

Clinical data support safety and efficacy of BI-207127 plus PEG-IFN/RBV in HCV genotype 1

Merck & Co. presents new CETP inhibitor prodrugs for hypercholesterolemia

Cempra presents preclinical and clinical phase I data on CEM-101 antibiotic

Roche discloses R&D highlights of the first quarter of 2010

BAL-30072 active against beta-lactamase-producing enterobacteria in vivo

Nerviano Medical Sciences discovers new B-raf inhibitors for cancer therapy

Lipocine earns milestone payment from Abbott for oral testosterone product

Tanezumab shows benefit in patients with interstitial cystitis

Tacrolimus improves symptoms of bladder pain syndrome/interstitial cystitis

Advanced Life Sciences reports preclinical data on Restanza as a biodefense countermeasure

Actelion launches epoprostenol for injection

Dainippon Sumitomo set to launch Metgluco in Japan

Abbott acquires Facet Biotech

Genmab begins new next-generation antibody program HuMax-cMet

Delcath reports phase III data on Delcath PHP System-delivered melphalan

Taiho launches 5-HT3 receptor antagonist Aloxi in Japan

Micromet achieves milestone under collaboration with Bayer Schering

Nuon advances NU-1618 to phase IIb for chronic hyperuricemia in gout

Morria Biopharmaceuticals to begin phase II trial of MRX-6

ImmunoCellular Therapeutics and University of Pennsylvania enter research agreement for ICT-107

ImmuneRegen and MPI Research to collaborate on development Homspera

Amylin, Lilly and Alkermes reply to FDA's complete response letter on Bydureon

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...